Variants in the LMNA
Introduction
The nuclear lamina is a proteinaceous layer underlying the inner membrane of the nucleus. Lamin-A/C, which is a nuclear intermediate filament protein, primarily interacts with cytoskeletal structures to provide cell adhesion functions. 1, 2 This interaction with cytoskeletal structures, such as α-actinin, desmin, and other linker proteins, may provide the machinery by which modulation of sarcolemma proteins, such as Nav1.5, might occur. 3, 4 Laminopathies are a series of genetic disorders, characterized by cardiac and skeletal anomalies. LMNA variants have been linked with these disorders, which include over 12 clinically heterogeneous syndromes. 1 Within the heart, LMNA variants are the major cause of primary dilated cardiomyopathy (DCM) with conduction system disease, including atrioventricular block (AVB). 5 Majority of the patients require pacemaker or implantable cardioverter-defibrillator (ICD) therapy to prevent sudden cardiac death. 6 However, due to a wide range of clinical presentations, the mechanisms of disease development are still poorly understood. It has been reported that the dysfunction of cardiac sodium channel (Na v 1.5) due to the genetic abnormalities of SCN5A, the gene encoding Na v 1.5, or its modulator proteins can cause cardiac conduction diseases. 7 We have identified two LMNA variants from patients presented with cardiac conduction defects AVB with and without DCM. We hypothesized that Lamin-A/C mutation may cause AVB by reducing Na v 1.5. To test that hypothesis, we performed patch-clamp studies in human embryonic kidney (HEK-293) cells expressing these variants. We showed that both variants significantly decreased the peak sodium current (I Na ) by approximately 60-70% and affected the voltage dependency of Na v 1.5. These findings suggest that the reduction of I Na by the LMNA variants might contribute to the patients' electrocardiographic phenotypes.
Materials and Methods
All patients and their family members were given oral explanations and written informed consents for the participation of this study. The study protocols were designed following the Helsinki declaration, and were approved by the institutional review board of Indiana University.
Patient characteristics
Case 1: The patient was a 34-year old Caucasian male. He was diagnosed with advanced AVB (3:1 AV conduction) with left anterior hemi block and right bundle branch block, and underwent pacemaker implantation ( Figure 1A ). However, he had no symptoms or echocardiogram findings indicating heart failure. Interestingly, his son presented with prenatal bradycardia and was diagnosed with second degree AVB at age two. Figure 1B shows the pedigree. There is no known family history of heart failure or sudden cardiac death. Case 2: The patient was a 34-year old Caucasian male with sudden cardiac arrest, DCM, and family history of DCM and arrhythmia. The patient had conduction N o n -c o m m e r c i a l u s e o n l y system disease, including first degree AVB and incomplete left bundle branch block, manifested by progressive PR prolongation and slightly increased QRS duration ( Figure  2A ). An electrocardiogram (ECG) taken two years later showed further lengthening of PR interval ( Figure 2B ). Although the patient underwent ICD implantation, his condition continued to deteriorate. He subsequently underwent orthotopic heart transplantation. Figure 2C shows the pedigree.
Genetic tests
The 
Construction of the plasmids and cell preparation
The cDNA of LMNA was purchased from OriGene Technologies (Rockville, MD). The cDNA of WT-LMNA (the ORF based upon NM_005572) was inserted in the pCMV6-AC-GFP vector. Mutant-LMNA constructs (p.R545H and p.A287Lfs*193) were made using site-direct mutagenesis kit (Qiagen). Sequences of the all plasmids were confirmed with direct sequencing.
Cell culture and transfection
HEK-293 cells were grown and maintained in IMDM (Life Technologies), supplemented with 10% fetal bovine serum (Sigma Aldrich). It has been reported that the splice variant lacking glutamine at position 1077 (Q1077del) reaches 65% of the SCN5A transcript in human heart. 8 Therefore, cells were transiently transfected with SCN5A-Q1077del and WT or mutant LMNAs for 48 hours using Effectene reagent (Qiagen) according to the manufacturer's instructions in 6-well plates. Each well was transfected with no more than 2 µg combined DNA. Cells were harvested using trypsin-EDTA (Life Technologies) for 1-2 mins, and transferred to the patch chamber for recording.
Patch-clamp experiments
Whole cell mode of the voltage-clamp technique was used in this study as described elsewhere. 9 Briefly, whole-cell configuration was made in Tyrode's solution. Pipette resistances were 1.5-3 MW. After achieving a giga seal, the test-pulse current was nulled by adjusting the pipette capacitance compensator with both fast and slow components. After break-in, the whole-cell charging transient was nulled by adjusting whole cell capacitance and series resistance. Voltage control protocols were generated with Axopatch 200B amplifier/Digidata 1440A acquisition system using pCLAMP-10 software (Molecular Devices/Axon, Sunnyvale, CA). Whole-cell recording was analyzed using Clampfit 10.2. For measuring I Na , we used Tyrode's solution as the bath solution. The pipette solution contained (in mM) NaF 10, CsF 110, CsCl 20, EGTA 10, and HEPES 10 (pH 7.35 adjusted with CsOH). All experiments were carried out at room temperature. 
Statistical analysis

LMNA variants found in two families of conduction disturbance defects
The genetic screening identified two variants in the LMNA (NM_005572) gene. In Case 1, a nucleotide change c.1634G>A was identified in both the proband and his son, which results in a point variant in exon 10, p.R545H. p.R545H has been known as a rare variant (rs142191737) whose frequency is 0.0002311 in gnomAD, the largest population database comprehending 123,136 exome sequences and 15,496 whole-genome sequences. In Case 2, a nucleotide change c.859delG was identified only in the proband, which results in a frame shift and premature termination codon in exon 5, p.A287Lfs*193. p.A287Lfs*193 was not found in gnomAD.
Lamin-A/C can alter peak I Na
Since impaired Na v 1.5 function has been reported to cause AVB, 10 WT-LMNA drastically increased the peak I Na (bottom trace) by approximately three-fold compared to the baseline SCN5A (WT-LMNA: 340±45 pA/pF, N=10 vs SCN5A only: 135±21 pA/pF, N=7, P<0.005). Figure 3A shows the current-voltage (I-V) relationships. The voltage-dependency of the steady-state activation and inactivation was also leftward-shifted by WT-LMNA ( Figure 3B , Table 1 ). Figure 4B shows the I-V relationships. p.R545H-LMNA failed to activate peak I Na by 70% compared to the cells transfected with WT-LMNA (WT: 340±45 pA/pF, N=10 vs p.R545H: 95±15 pA/pF, N=10, P<0.005). Figure 4C shows that p.R545H-LMNA shifted the voltagedependency of the steady-state inactivation towards positive compared to WT-LMNA (V h : WT, -93.20±0.89 mV, N=15 vs p.R545H, -87.64±0.91 mV, N=24, P<0.005). However, the steady-state activation was unaffected (V h : WT, -52.38±0.41 mV, N=10 vs p.R545H, -50.42±0.32 mV, N=10, N.S.).
Next, we examined the effect of p.A287Lfs*193-LMNA on I Na , and compared the parameters with WT-LMNA. Figure 5A shows the representative superimposed current traces of I Na obtained from cells transfected with SCN5A and WT-LMNA or SCN5A and p.A287Lfs*193-LMNA. p.A287Lfs*193-LMNA significantly decreased the peak I Na by 62% compared to the WT-LMNA (WT: 340±45 pA/pF, N=10 vs p.A287Lfs*193: 132 ±28 pA/pF, N=9, P<0.005). Figure 5B shows the I-V relationships. Figure 5C shows 
Discussion and Conclusions
In this study, we found two variants in the LMNA gene, p.R545H and p.A287Lfs*193, in two patients who showed AVB. The latter patient also had cardiomyopathy.
Our patch-clamp experiments using HEK-293 cells showed that the peak I Na was reduced when these two variants were co-expressed with SCN5A. The data indicate that these LMNA variants may fail to activate Na v 1.5 properly, resulting in the reduction of I Na compared to cells transfected with WT-LMNA. Since the magnitudes of I Na reduction was greater than 50%, this might account for the patients' ECG phenotypes.
Several previous studies, including ours, demonstrated that the function of Na v 1.5 can be modulated via various cytoskeletal proteins such as actin, 3 α-actinin-2, 11 syntrophin and dystrophin complex, 12 and ZASP/Telethonin cytoskeletal complex. 4 The proposed underlying mechanisms of these functional modifications of Na v 1.5 by the cytoskeletal proteins are either alteration of protein expression or modification of ion channel kinetics. However, the exact mechanisms remain elusive. On the contrary, it has been reported that the structural proteins of nucleus and nucleoskeleton may link with cytoskeletal proteins, called linker of nucleoskeleton and cytoskeleton (LINC) complex. For example, nesprin 1α is essential to determine the position of nucleus in muscle cells and cytoskeletal muscle functions. 13 Nesprins interact with desmins and microtubles that play important role in the function of muscles. 14, 15 Taken these together, it is reasonable to speculate that the structural changes of Lamin-A/C, caused by genetic variants, can affect the function of Na v 1.5. In our cases, the first patient showed advanced AVB without any heart failure symptoms, and he has no family history of cardiomyopathy. On the contrary, the second patient showed both AVB and cardiomyopathy. The patient's mother showed obvious DCM, and her brother and father had symptoms suggesting cardiomyopathy. The question remains whether or not the ECG phenotypes in these two individuals are caused by the same underlying mechanism. As we reported in our previous studies, patients with abnormal cytoskeletal structures may show their arrhythmia phenotypes preceding their cardiomyopathy phenotypes. 4, 16 Since crystallography studies were not available, we do not know the actual structural abnormalities caused by these two variants of LMNA. The first patient's LMNA abnormality is a single nucleotide variant (SNV) in exon 10, and the second patient's LMNA abnormality in exon 5 is a single nucleotide deletion, leading to a frameshift and premature termination of LMNA. Since WT-LMNA activated the I Na , the mutated proteins might have failed to activate the I Na properly (Figure 4A -B; Figure 5A -B). In addition, p.A287Lfs*193-LMNA might be degraded by nonsense-mediated mRNA decay in actual human hearts as well. 17 The latter genotype is known to be associated with more severe clinical manifestations of the disease. 18 Interestingly, p.R545H-LMNA was found in Dunnigan-type 2 familial partial lipodystrophy (FPLD2). 19 However, in the clinical record we obtained, no evidence that a FPLD2 phenotype was documented. The clinical manifestation of this variant might be similar to what occurs in Anderson-Tawil syndrome (Long-QT 7). 20 Although patients with pathogenic variants in the causative gene of LQT7, KCNJ2, can present with various dysmorphic features, periodic paralysis, and QT-prolongation, the clinical phenotypes vary a lot depending upon individual and age. Isolated LQTS was also observed. Therefore, long-term close follow up is warranted for our patients. There are several limitations in our study. Since biopsies and detailed histological studies of the patients' hearts were not performed, we cannot exclude a possibility that the fibrosis associated with cardiomyopathy was the main cause of the conduction disturbances as mentioned above. Since detailed information regarding studies for ischemic heart diseases was not provided, we cannot rule out the ischemic causes for their ECG phenotypes. However, there were no underlying factors known to increase the risk of ischemic heart disease and any symptoms suggesting ischemic heart diseases. In addition, the patients' ages are relatively young (3 y.o. and 34 y.o.), and ECG did not show any apparent ischemic changes. Thus, we think ischemic causes are less likely. In our study, a heterologous system using HEK-293 cells was employed to investigate the effects of WT and mutant LMNAs on the function of hNa v 1.5. Since the cytoskeletal structure, signal transductions, and protein expression profiles of HEK-293 cells are different from cardiomyocytes, we do not know if the reduction of I Na by LMNA variants actually took place in the patients' hearts. This limitation applies to all HEK-293 studies, which might be improved if we use different assay models such as animal models and iPSC-derived cardiomyocytes. However, these are beyond the scope of current study. In addition, since the detailed study in regard to protein-protein interaction and single channel recording of Na v 1. 5 were not yet performed, we could not reveal exact underlying mechanisms of how LMNA can affect I Na . Therefore, further studies are warranted in the future.
Article
In conclusion, disease-causing LMNA variants may reduce peak I Na when coexpressed with SCN5A in HEK-293 cells. These findings suggest that reduced peak I Na may play a role in the development of AVB in these two families.
